An artificial intelligence algorithm for co-clustering to help in pharmacovigilance before and during the COVID-19 pandemic
Description
CONCLUSIONS: Co-clustering and dLBM appear as promising tools to explore large pharmacovigilance databases. They allow, 'unsupervisedly', the detection, exploration and strengthening of safety signals, facilitating the analysis of massive upsurges of